GLP-1 market shifts as insurance coverage and competition evolve

The GLP-1 medication market is undergoing significant changes driven by new competition, evolving administration methods, and shifts in insurance coverage. While these drugs have transformed the treatment of diabetes and obesity, the landscape is shifting toward cheaper alternatives, including the arrival of generic semaglutide in markets such as India and Canada.

New scientific developments are also emerging, such as the potential for oral GLP-1s to create a separate market segment and the development of monthly dosing options like Amgen’s MariTide. Industry experts suggest that weight maintenance will become the next major competitive frontier in metabolic health.

Simultaneously, access to these medications is facing challenges in the United States. Although many private employer plans previously covered GLP-1s for weight loss, some private insurers are now pulling back on coverage. This trend creates a dilemma for patients who may face high out-of-pocket costs, potentially forcing them to choose between financial strain and discontinuing medications that impact long-term health risks like heart and kidney disease.